


Navigating the future for HR+/HER2– metastatic breast cancer

Saturday 8 October 2016, 13.00–14.30

Stockholm Auditorium, Bella Center
Copenhagen, Denmark



Dear Colleague,

On behalf of the faculty, I am pleased to invite you to the Pfizer Oncology satellite symposium '**Navigating the future for HR+/HER2– metastatic breast cancer**'. The symposium will be held on Saturday 8 October 2016 at 13.00–14.30, during the ESMO 2016 Congress.

A significant unmet need still exists in treating patients with HR+/HER2– breast cancer, to extend time to progression and maintain quality of life. This year, we have already observed an explosion of data for the CDK4/6 inhibitors, in addition to expanding our knowledge of targeted therapies in the real world.

During our symposium, a distinguished international faculty will review the latest clinical trial evidence for the CDK4/6 inhibitors, to include experiences from the clinic and case-based discussion. Another key focus will be exploring how biomarkers may impact patient selection and the future treatment landscape.

I look forward to welcoming you to Copenhagen and I hope you will join us for what promises to be an engaging and highly educational meeting.

Best regards,

Stephen Johnston, Chair

*Professor of Breast Cancer Medicine and Consultant Medical Oncologist
The Royal Marsden and The Institute of Cancer Research, London, UK*

Programme

Chair: Stephen Johnston (UK)

13.00–13.10	The journey so far: HR+/HER2– mBC in 2016	Stephen Johnston (UK)
13.10–13.30	New directions: CDK4/6 inhibitors in the management of HR+/HER2– mBC	Nicholas Turner (UK)
13.30–13.50	Scan the horizon: How will biomarkers shape the landscape?	Fabrice André (France)
13.50–14.10	Optimal management of CDK4/6 inhibitors: Learning from experience	Hope S. Rugo (USA)
14.10–14.25	Panel discussion	All faculty
14.25–14.30	Closing remarks	Stephen Johnston (UK)